A Food and Drug Administration-approved Asthma Therapeutic Agent Impacts Amyloid β in the Brain in a Transgenic Model of Alzheimer Disease
Open Access
- 1 January 2015
- journal article
- research article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 290 (4) , 1966-1978
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Interaction of the Molecular Chaperone DNAJB6 with Growing Amyloid-beta 42 (Aβ42) Aggregates Leads to Sub-stoichiometric Inhibition of Amyloid FormationJournal of Biological Chemistry, 2014
- A mutation in APP protects against Alzheimer’s disease and age-related cognitive declineNature, 2012
- 3,3′,4′,5,5′-Pentahydroxyflavone is a potent inhibitor of amyloid β fibril formationNeuroscience Letters, 2012
- Novel microdialysis method to assess neuropeptides and large molecules in free-moving mouseNeuroscience, 2011
- Intraneuronal β-amyloid accumulation and synapse pathology in Alzheimer’s diseaseActa Neuropathologica, 2010
- Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaquesProceedings of the National Academy of Sciences, 2009
- In VivoAssessment of Brain Interstitial Fluid with Microdialysis Reveals Plaque-Associated Changes in Amyloid-β Metabolism and Half-LifeJournal of Neuroscience, 2003
- The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to TherapeuticsScience, 2002
- Pharmacologic Therapy for Asthma: Overview and Historical PerspectiveThe Journal of Clinical Pharmacology, 1999
- Changes induced by sodium cromoglycate in brain catecholamine turnover in morphine dependent and abstinent micePsychopharmacology, 1995